The GLP-1 CVD outcome trials a) Elixa (Lexisenatide) b) Leader (Liraglutide) c) Sustain-6 (Semaglutide) d) Exscel (Weekly Exenatide) e) Harmony (Albiglutide) f) Rewind (Dulaglutide) g) Pioneer 6 (Oral Semaglutide) Elixa Study (Evaluation of Lixisenatide) In ELIXA, the investigational GLP-1 receptor agonist, lixisenatide, neither reduced nor increased cardiovascular events compared with placebo
Why is comprehensive support important with GLP-1 drugs
IV therapy is a medical procedure that involves the delivery of fluids, medications, or nutrients directly into the bloodstream through a vein
GSSG (oxidized glutathione) can be reduced back to GSH by GSSG reductase (GR) at the expense of NADPH, completing the redox recycling cycle
Taurine modulates calcium influx through L-type voltage-gated calcium channels in isolated cochlear outer hair cells in guinea pigs
N Engl J Med 377:12281239 Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
